



Daniel Lednicher

# Strategies for Organic Drug Synthesis and Design

Second Edition



 WILEY

R914  
L473-2  
E-2

---

# STRATEGIES FOR ORGANIC DRUG SYNTHESIS AND DESIGN

---

Second Edition

DANIEL LEDNICER



**WILEY**



E2009000057

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2009 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey  
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in variety of electronic formats. Some content that appears in print may not be available in electronic format. For more information about Wiley products, visit our web site at [www.wiley.com](http://www.wiley.com).

*Library of Congress Cataloging-in-Publication Data is available.*

ISBN 978-0-470-19039-5

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

# STRATEGIES FOR ORGANIC DRUG SYNTHESIS AND DESIGN

To the memory of now-defunct laboratories where once I practiced  
my craft: Building H at G.D. Searle in Skokie, Upjohn's Building 25 in  
Kalamazoo and the diminutive Chemistry Annex at the Adria  
Laboratories just outside Dublin, Ohio.



# PREFACE

---

“One of the most interesting aspects of organic chemistry is that of dealing with the building-up of complex substances from simpler ones. The synthesis of organic compounds, whether for scientific or industrial purposes, has been very important in the development of the science and is still of great importance today.”

Those words, set down 80 years ago as the opening for a chapter on organic synthesis in Conant's pioneering textbook *Organic Chemistry*,\* still very aptly describes the important role held by that aspect of the discipline. The use of organic transformations for the preparation of compounds with more or less complex structures has had a profound influence on both organic chemistry and, more importantly, on modern civilization. One need only bring to mind medicinal agents at one extreme and, on the other, the monomers used for the plethora of polymers that have provided the basis for a whole new materials science. The practice of organic synthesis covers an extremely broad range, from the highly practical, economically driven preparation of a tonnage chemical to a multistep, very elegant enantiospecific synthesis of a complex natural product. This very diversity may account for the relative paucity of books devoted specifically to the subject.

The manipulation used for the preparation of therapeutic agents seems to offer a middle ground between those extremes in complexity. The published syntheses for these agents are typically relatively short, seldom exceeding 10 or so steps. The target compounds for these syntheses do, however, cover a very wide range of structural types, encompassing both carbocyclic and heterocyclic compounds. The chemistry moreover includes a very broad selection of organic reactions. The published syntheses most often describe the route that was used in the discovery of

\*Conant, James B.; *Organic Chemistry*, Macmillan, New York, 1928, p. 117.

some new compound. Some exotic and versatile reagents are used since reaction conditions are not circumscribed by their applicability to plant processes. The syntheses of therapeutic agents thus offer a good didactic tool.

The first edition of this book comprised a selection of syntheses from the five-volume series *The Organic Chemistry of Drug Synthesis* that was in press at that time. Examples were chosen to illustrate the strategy and the organic transformations that were used to prepare the various structural classes that had been investigated as drugs. Research over the decade that has elapsed since the appearance of that first edition saw the birth of many new drugs and perhaps, more importantly, drugs that addressed new therapeutic areas. These also on occasion invoked the use of novel chemistry. These new developments strongly suggested that it was time to bring the book up to date. Many of these new developments are included in this second edition of *Strategies for Organic Drug Synthesis and Design*. This new work is taken from the two volumes of *The Organic Chemistry of Drug Synthesis* that appeared after the publication of the first edition (Volume 6, 1999, Volume 7, 2008).

One of the main motivations that led to the writing of the original book, entitled *The Organic Chemistry of Drug Synthesis*, was curiosity as to how various classes of drugs were in fact prepared. The enormous number of compounds reported in the literature as potential drugs led to an early decision to restrict the book to those agents that had been granted nonproprietary names. This filtering mechanism was based on the assumption that, in the judgment of the sponsor, the compound in question showed sufficient activity to merit eventual clinical evaluation. Within a few years of the publication of *The Organic Chemistry of Drug Synthesis*, a followup volume was issued to bring the coverage up to date and to make up for gaps in the coverage of the original book. Between them, the two books included a large majority of compounds that had been granted generic names up to that time. The subsequent three volumes of what became a series appeared roughly semidecenial in order to cover the syntheses of compounds granted generic names during those intervals. A full decade elapsed before the most recent volume appeared due to a slowdown in the appearance of new compounds granted USAN.

The focus of this book differs from that of the series in that it is aimed more specifically at the organic chemistry used for preparation of the drugs in question. Drugs have been selected mainly for the illustrative value of the chemistry used for their synthesis, and hence, too, the inclusion of the rather extensive "Reaction Index." The structures in chemical schemes have been drawn with special attention to clarifying the individual reactions; rearrangements, starting materials, and products, for example, are shown in similar views. The very brief discussions of medicinal chemistry are intended to provide the reader with a feel for the activities and occasionally the mechanisms of action of various drugs. Salient principles of drug action are presented in capsule form at appropriate points; by the same token, the claimed therapeutic effect of each agent is noted along with the discussion of its preparation. The pharmacological presentations are thus abbreviated over those that occur in the series. Interested readers should consult any of a wide selection of medicinal chemistry or pharmacology texts such as *Burger's Medicinal Chemistry* for fuller and more authoritative discussions.

A word on bibliographic references is in order at this point. The patents that comprise a significant proportion of references were often not readily accessible 10 years ago; to help the reader, those were usually accompanied by a reference to that patent recorded in *Chemical Abstracts*. The ready availability of actual images to U.S. patents ([www.uspto.gov](http://www.uspto.gov)) and those from abroad (<http://ep.espacenet.com>) has led to the deletion of the now-superfluous *Chemical Abstracts* reference.

DANIEL LEDNICER  
North Bethesda, MD  
March 2008



# CONTENTS

---

## PREFACE

xv

## 1 PROSTAGLANDINS, PEPTIDOMIMETIC COMPOUNDS, AND RETINOIDS

1

- 1.1 Prostaglandins / 1
- 1.2 Peptidomimetic Compounds / 19
  - 1.2.1 Protease Inhibitors / 19
    - 1.2.1.1 Introduction / 19
    - 1.2.1.2 Renin Inhibitors / 20
    - 1.2.1.3 Antiviral Compounds / 22
  - 1.2.2 Fibrinogen Receptor Antagonists / 30
  - 1.2.3 Antitumor Peptidomimetic / 34
- 1.3 Retinoids / 35
- 1.4 A Miscellaneous Drug / 38
- References / 40

## 2 DRUGS BASED ON A SUBSTITUTED BENZENE RING

43

- 2.1 Arylethanolamines / 43
- 2.2 Aryloxypropanolamines / 54
  - 2.2.1  $\beta$ -Blockers / 54
  - 2.2.2 Non-Tricyclic Antidepressants (SSRIs) / 57

- 2.3 Arylsulfonic Acid Derivatives / 61
  - 2.3.1 Antibacterial Sulfonamides / 61
  - 2.3.2 Diuretic Agents / 63
  - 2.3.3 Oral Hypoglycemic Agents / 65
  - 2.3.4 Miscellaneous Arylsulfonamides / 70
- 2.4 Arylacetic and Arylpropionic Acids / 71
  - 2.4.1 Arylacetic acid "Fenacs" / 71
  - 2.4.2 Arylpropionic Acid "Profens" / 75
  - 2.4.3 Arylacetamide Antiarrhythmic Compounds / 78
- 2.5 Leukotriene Antagonists / 81
- 2.6 Miscellaneous Compounds / 84
- References / 86

### 3 INDENES, NAPHTHALENES, AND OTHER POLYCYCLIC AROMATIC COMPOUNDS

89

- 3.1 Indenes / 90
- 3.2 Naphthalenes / 94
  - 3.2.1 Antifungal Agents / 94
  - 3.2.2 Miscellaneous Naphthalenes / 97
- 3.3 Partly Reduced Naphthalenes / 99
  - 3.3.1 Bicyclic Retinoids / 99
  - 3.3.2 Another  $\beta$ -Blocker / 101
  - 3.3.3 Aminotetralin CNS Agents / 102
- 3.4 Tricyclic Compounds / 105
  - 3.4.1 Dibenzocycloheptane and Dibenzocycloheptene Antidepressants / 105
  - 3.4.2 Antidepressants Based on Dihydroanthracenes / 110
  - 3.4.3 Anthraquinones: The "Antrone" Chemotherapy Agents / 113
- References / 116

### 4 STEROIDS; PART 1: ESTRANES, GONANES, AND ANDROSTANES

119

- 4.1 Introduction / 119
- 4.2 Steroid Starting Materials / 120
  - 4.2.1 From Diosgenin / 121
  - 4.2.2 From Soybean Sterols / 121
- 4.3 Estranes / 123
  - 4.3.1 Synthesis of Estranes / 123
  - 4.3.2 Drugs Based on Estranes / 125

- 4.4 Gonanes, the 19-nor Steroids / 128
  - 4.4.1 Progestational Compounds / 128
  - 4.4.2 Progesterone Antagonists / 137
  - 4.4.3 Androgenic Compounds / 140
- 4.5 Androstanes / 142
  - 4.5.1 Starting Materials / 142
  - 4.5.2 Androgenic Compounds / 143
  - 4.5.3 Antiandrogens / 150
  - 4.5.4 Aldosterone Antagonists / 153
- References / 157

## **5 STEROIDS; PART 2: COMPOUNDS RELATED TO PROGESTERONE, CORTISONE, AND CHOLESTEROL 161**

- 5.1 Introduction / 161
- 5.2 Progestins / 161
- 5.3 Corticosteroids / 169
- 5.4 Compounds Derived from Cholesterol / 186
- References / 189

## **6 NONSTEROIDAL SEX HORMONES AND THEIR ANTAGONISTS 191**

- 6.1 Introduction / 191
- 6.2 Estrogens / 191
  - 6.2.1 Nonsteroidal Estrogens / 191
  - 6.2.2 Nonsteroid Estrogen Antagonists / 195
    - 6.2.2.1 Arylethylenes / 195
    - 6.2.2.2 Carbocyclic Ethylenes Fused to a Benzene Ring / 200
    - 6.2.2.3 Heterocyclic Ethylenes Fused to a Benzene Ring / 203
  - 6.2.3 Nonsteroid Androgen Antagonists / 207
  - 6.2.4 A Nonsteroid Progestin Agonist / 209
- References / 210

## **7 OPIOID ANALGESICS 213**

- 7.1 Introduction / 213
- 7.2 Drugs Derived from Morphine / 214
- 7.3 Compounds Prepared from Thebaine / 216

- 7.4 Morphinans / 219
- 7.5 Benzomorphans / 223
- 7.6 Analgesics Based on Nonfused Piperidines / 226
  - 7.6.1 4-Arylpiperidines: Meperidine and Its Analogues / 226
  - 7.6.2 4-Amidopiperidines: Compounds Related to Fentanyl / 229
  - 7.6.3 Miscellaneous Compounds / 234
    - 7.6.3.1 1,2-Bisaminoceclohexanes / 234
    - 7.6.3.2 Open Chain Compounds / 236
- References / 237

## **8 DRUGS BASED ON FIVE-MEMBERED HETEROCYCLES 239**

- 8.1 Introduction / 239
- 8.2 Rings that Contain One Heteroatom / 239
  - 8.2.1 Furans / 239
  - 8.2.2 Pyrrole and Its Derivatives / 241
    - 8.2.2.1 NSAIDS and a “Statin” / 241
    - 8.2.2.2 ACE Inhibitors / 246
    - 8.2.2.3 Miscellaneous Compounds / 251
- 8.3 Rings that Contain Two Heteroatoms / 258
  - 8.3.1 Cyclooxygenase 2 (COX-2) Inhibitor NSAIDs / 258
  - 8.3.2 Oxazoles, Isoxazoles, and their Derivatives / 262
  - 8.3.3 Imidazoles / 269
  - 8.3.4 Imidazolines / 287
  - 8.3.5 Modified Imidazoles / 291
  - 8.3.6 Pyrrazolones and Pyrrazolodiones / 295
  - 8.3.7 Thiazoles and Related Sulfur–Nitrogen-Containing Heterocycles / 298
- 8.4 Rings that Contain Three or More Heteroatoms / 304
  - 8.4.1 1,2,4-Oxadiazoles / 304
  - 8.4.2 Triazoles / 306
  - 8.4.3 Thiadiazoles / 311
  - 8.4.4 Tetrazoles / 313
- References / 314

## **9 DRUGS BASED ON SIX-MEMBERED HETEROCYCLES 319**

- 9.1 Rings that Contain One Heteroatom / 319
  - 9.1.1 Pyrans / 319
  - 9.1.2 Pyridines / 323
  - 9.1.3 1,4-Dihydropyridines / 329

- 9.1.4 Piperidines / 332
  - 9.1.4.1 Psychotropic Compounds / 332
  - 9.1.4.2 Miscellaneous Piperidines / 336
- 9.1.5 Pyridones and Glutarimides / 337
- 9.2 Rings that Contain Two Heteroatoms / 341
  - 9.2.1 Pyridazines / 341
  - 9.2.2 Pyrimidines / 344
    - 9.2.2.1 Antibacterial Agents / 344
    - 9.2.2.2 Antiviral and Antineoplastic Pyrimidines / 348
    - 9.2.2.3 Miscellaneous Pyrimidines / 356
  - 9.2.3 Pyrimidones / 359
  - 9.2.4 Triketopyrimidines: The Barbiturates / 363
  - 9.2.5 Pyrazines / 364
  - 9.2.6 Piperazines / 366
- 9.3 Rings Containing Three Heteroatoms: The Triazines / 376
- References / 379

## **10 FIVE-MEMBERED HETEROCYCLES FUSED TO A BENZENE RING**

**383**

- 10.1 Compounds that Contain One Heteroatom / 383
  - 10.1.1 Benzofurans / 383
  - 10.1.2 Indoles / 389
  - 10.1.3 Indolines and Isoindolines / 401
- 10.2 Compounds that Contain Two Heteroatoms / 407
  - 10.2.1 Indazoles / 407
  - 10.2.2 Benzimidazoles / 408
  - 10.2.3 Benzoxazoles and Benzisoxazoles / 419
  - 10.2.4 Benzothiazoles / 421
- 10.3 Compounds that Contain Three Heteroatoms / 423
- References / 425

## **11 SIX-MEMBERED HETEROCYCLES FUSED TO A BENZENE RING**

**429**

- 11.1 Compounds that Contain One Heteroatom / 429
  - 11.1.1 Coumarins / 429
  - 11.1.2 Chromones / 432
  - 11.1.3 Benzopyrans / 435
  - 11.1.4 Quinolines / 440
    - 11.1.4.1 Antimalarial Compounds / 440
    - 11.1.4.2 Other Quinolines / 444

11.1.5	Quinolones / 454
11.1.5.1	Antibacterial Agents / 454
11.1.5.2	Miscellaneous Quinolones / 462
11.1.6	Isoquinoline and Its Derivatives / 463
11.2	Compounds that Contain Two Heteroatoms / 467
11.2.1	Benzodioxans / 467
11.2.2	Miscellaneous Fused Rings that Include Oxygen / 470
11.2.3	Cinnolines and Phthalazines / 472
11.2.4	Quinazolines / 476
11.2.5	Quinazolones / 482
11.3	Compounds that Contain Three Heteroatoms / 488
	References / 490

## **12 SEVEN-MEMBERED HETEROCYCLIC RINGS FUSED TO BENZENE 495**

12.1	Compounds with a Single Heterocyclic Atom / 495
12.2	Compounds with Two Heteroatoms / 499
12.2.1	Benzodiazepine Anxiolytic Agents / 499
12.2.2	Other Seven-Membered Heterocycles Fused to a Benzene Ring / 508
	References / 513

## **13 HETEROCYCLES FUSED TO TWO AROMATIC RINGS 515**

13.1	Compounds Containing a Single Heteroatom / 515
13.1.1	Derivatives of Dibenzopyran and Dibenzoxepin / 515
13.1.2	Dibenzo Heterocycles Containing One Ring Nitrogen Atom / 520
13.1.3	Dibenzo Heterocycles with One Sulfur Atom / 527
13.2	Compounds Containing Two Heteroatoms / 532
13.2.1	Phenothiazines / 532
13.2.2	A Dibenzoxazine / 535
13.2.3	Dibenzodiazepines, Dibenzoxazepines, and a Benzothiazepine / 536
13.3	Pyridine-Based Fused Tricyclic Compounds / 540
	References / 543

## **14 BETA LACTAM ANTIBIOTICS 545**

14.1	Penicillins / 546
14.2	Cephalosporins / 558

14.3 Monobactams / 572

References / 574

**15 HETEROCYCLES FUSED TO OTHER HETEROCYCLIC RINGS** **577**

15.1 Two Fused Five-Membered Rings / 577

15.2 Five-Membered Heterocycles Fused to Six-Membered Rings / 580

15.2.1 Compounds Containing Two Heteroatoms / 580

15.2.2 Compounds Containing Three Heteroatoms / 586

15.2.3 Compounds with Four Heteroatoms / 593

15.2.3.1 Purines / 593

15.3 Two Fused Six-Membered Rings / 611

15.3.1 Compounds Related to Methotrexate / 611

15.3.2 Other Fused Heterocyclic Compounds / 615

15.4 Heterodiazepines / 620

15.5 Heterocyclic Compounds with Three or More Rings / 622

References / 629

**SUBJECT INDEX** **633**

**REACTION INDEX** **651**

**CROSS INDEX OF BIOLOGICAL ACTIVITIES** **671**

## CHAPTER 1

---

# PROSTAGLANDINS, PEPTIDOMIMETIC COMPOUNDS, AND RETINOIDS

---


### 1.1. PROSTAGLANDINS

It is highly likely that those not themselves involved in scientific research perceive the development of new knowledge within a given area of science as a linear process. The popular view is that the understanding of the specific details of any complex system depends on prior knowledge of the system as a whole. This knowledge is in turn believed to derive from the systematic stepwise study of the particular system in question. The piecemeal, almost haphazard, way in which the details of the existence and later the detailed exposition of the arachidonic acid cascade were put together is much more akin to the assembly of a very complex jigsaw puzzle. This particular puzzle includes the added complication of incorporating many pieces that did not in fact fit the picture that was finally revealed; the pieces that would in the end fit were also found at very different times.

The puzzle had its inception with the independent observation in the early 1930s by Kurzok and Lieb [1] and later von Euler [2] that seminal fluid contained a substance that caused the contraction of isolated guinea pig muscle strips. The latter named this putative compound prostaglandin in the belief that it originated in the prostate gland; the ubiquity of those substances was only uncovered several



decades later. The discovery remained an isolated oddity until the mid-1960s, by which time methods for chromatographic separation of complex mixtures of polar compounds and spectroscopic methods for structure determination were sufficiently advanced for the characterization of humoral substances that occur at very low levels. The isolation and structural assignment of the first two natural prostaglandins,  $\text{PGE}_1$  and  $\text{PGF}_2$ , were accomplished by Bergstrom and his colleagues at the Karolinska Institute [3]. (The letter that follows PG probably initially referred to the order in which the compounds were isolated: E refers to 9-keto-11-hydroxy compounds and F refers to 9,11-diols; the subscripts refer to the number of double bonds.) The carbon atoms of the hypothetical, fully saturated, but otherwise unsubstituted carbon skeleton, prostanoic acid, are numbered sequentially starting with the carboxylic acid as 1, and then running around the ring and resuming along the other side chain.



The identification of these two prostaglandins in combination with their very high potency in isolated muscle preparations suggested that they might be the first of a large class of new hormonal agents. Extensive research in the laboratories of the pharmaceutical industry had successfully developed a large group of new steroid-based drugs from earlier similar leads in that class of hormones; this encouraged the belief that the prostaglandins provided an avenue that would lead to a broad new class of drugs. As in the case of the steroids, exploration of the pharmacology of the prostaglandins was initially constrained by the scarcity of supplies. The low levels at which the compounds were present, as well as their limited stability, forced the pace toward developing synthetic methods for those compounds. The anticipated need for analogues served as an additional incentive for elaborating routes for their synthesis.

Further work on the isolation of related compounds from mammalian sources, which spanned several decades, led to the identification of a large group of structurally related substances. Investigations on their biosynthesis made it evident that all eventually arise from the oxidation of the endogenous substance, arachidonic acid. The individual products induce a variety of very potent biological responses, with inflammation predominating. Arachidonic acid, once freed from lipids by the enzyme phospholipase  $A_2$ , can enter one of two branches of the arachidonic acid